Literature DB >> 24526742

Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome.

Anita K McElroy1, Bobbie R Erickson2, Timothy D Flietstra2, Pierre E Rollin2, Stuart T Nichol2, Jonathan S Towner2, Christina F Spiropoulou2.   

Abstract

BACKGROUND: Ebola hemorrhagic fever (EHF) outbreaks occur sporadically in Africa and result in high rates of death. The 2000-2001 outbreak of Sudan virus-associated EHF in the Gulu district of Uganda led to 425 cases, of which 216 were laboratory confirmed, making it the largest EHF outbreak on record. Serum specimens from this outbreak had been preserved in liquid nitrogen from the time of collection and were available for analysis.
METHODS: Available samples were tested using a series of multiplex assays to measure the concentrations of 55 biomarkers. The data were analyzed to identify statistically significant associations between the tested biomarkers and hemorrhagic manifestations, viremia, and/or death.
RESULTS: Death, hemorrhage, and viremia were independently associated with elevated levels of several chemokines and cytokines. Death and hemorrhage were associated with elevated thrombomodulin and ferritin levels. Hemorrhage was also associated with elevated levels of soluble intracellular adhesion molecule. Viremia was independently associated with elevated levels of tissue factor and tissue plasminogen activator. Finally, samples from nonfatal cases had higher levels of sCD40L.
CONCLUSIONS: These novel associations provide a better understanding of EHF pathophysiology and a starting point for researching new potential targets for therapeutic interventions. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  Ebola virus; Gulu; biomarkers; hemorrhage; hemorrhagic fever virus

Mesh:

Substances:

Year:  2014        PMID: 24526742      PMCID: PMC4172044          DOI: 10.1093/infdis/jiu088

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  32 in total

1.  An outbreak of Ebola in Uganda.

Authors:  S I Okware; F G Omaswa; S Zaramba; A Opio; J J Lutwama; J Kamugisha; E B Rwaguma; P Kagwa; M Lamunu
Journal:  Trop Med Int Health       Date:  2002-12       Impact factor: 2.622

2.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.

Authors:  Thomas W Geisbert; Lisa E Hensley; Peter B Jahrling; Tom Larsen; Joan B Geisbert; Jason Paragas; Howard A Young; Terry M Fredeking; William E Rote; George P Vlasuk
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

3.  Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients.

Authors:  M A Bwaka; M J Bonnet; P Calain; R Colebunders; A De Roo; Y Guimard; K R Katwiki; K Kibadi; M A Kipasa; K J Kuvula; B B Mapanda; M Massamba; K D Mupapa; J J Muyembe-Tamfum; E Ndaberey; C J Peters; P E Rollin; E Van den Enden; E Van den Enden
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

4.  Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection.

Authors:  F Villinger; P E Rollin; S S Brar; N F Chikkala; J Winter; J B Sundstrom; S R Zaki; R Swanepoel; A A Ansari; C J Peters
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

5.  Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.

Authors:  Nadia Wauquier; Pierre Becquart; Cindy Padilla; Sylvain Baize; Eric M Leroy
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

6.  Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus.

Authors:  Pierre E Rollin; Daniel G Bausch; Anthony Sanchez
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

7.  Immunoglobulin levels in haemophiliacs at HIV seroconversion and during follow up.

Authors:  M Blombäck; H Kjellman; S Schulman; N Egberg; B Böttiger; B Wiechel
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

8.  Prevalence of high serum and red cell ferritin levels in HIV-infected patients.

Authors:  A Riera; E Gimferrer; J Cadafalch; A Remacha; S Martin
Journal:  Haematologica       Date:  1994 Mar-Apr       Impact factor: 9.941

9.  Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome.

Authors:  Jonathan S Towner; Pierre E Rollin; Daniel G Bausch; Anthony Sanchez; Sharon M Crary; Martin Vincent; William F Lee; Christina F Spiropoulou; Thomas G Ksiazek; Mathew Lukwiya; Felix Kaducu; Robert Downing; Stuart T Nichol
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Sequence-based human leukocyte antigen-B typing of patients infected with Ebola virus in Uganda in 2000: identification of alleles associated with fatal and nonfatal disease outcomes.

Authors:  Anthony Sanchez; Kent E Wagoner; Pierre E Rollin
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

View more
  89 in total

1.  Why and How Is Hyperferritinemic Sepsis Different From Sepsis Without Hyperferritinemia?

Authors:  Joseph A Carcillo; Kate K Kernan; Christopher M Horvat; Dennis W Simon; Rajesh K Aneja
Journal:  Pediatr Crit Care Med       Date:  2020-05       Impact factor: 3.624

Review 2.  Ebola Virus Disease: Focus on Children.

Authors:  Athena P Kourtis; Kristie Appelgren; Michelle S Chevalier; Anita McElroy
Journal:  Pediatr Infect Dis J       Date:  2015-08       Impact factor: 2.129

3.  Human Biomarkers of Outcome Following Rift Valley Fever Virus Infection.

Authors:  Anita K McElroy; Jessica R Harmon; Timothy Flietstra; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2018-10-20       Impact factor: 5.226

4.  Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease.

Authors:  Anita K McElroy; Jessica R Harmon; Timothy D Flietstra; Shelley Campbell; Aneesh K Mehta; Colleen S Kraft; Marshall G Lyon; Jay B Varkey; Bruce S Ribner; Christopher J Kratochvil; Peter C Iwen; Philip W Smith; Rafi Ahmed; Stuart T Nichol; Christina F Spiropoulou
Journal:  Clin Infect Dis       Date:  2016-06-27       Impact factor: 9.079

Review 5.  Ebola virus disease.

Authors:  Nicholas J Beeching; Manuel Fenech; Catherine F Houlihan
Journal:  BMJ       Date:  2014-12-10

6.  Immunomodulatory adjunctive treatment options for Ebola virus disease patients: another view.

Authors:  David S Fedson
Journal:  Intensive Care Med       Date:  2015-06-03       Impact factor: 17.440

Review 7.  Ebola hemorrhagic fever: genetic biomarkers and vaccine development.

Authors:  Erin Oliphant
Journal:  Genet Test Mol Biomarkers       Date:  2014-10-23

8.  Understanding organ dysfunction in Ebola virus disease.

Authors:  Tom E Fletcher; Robert A Fowler; Nicholas J Beeching
Journal:  Intensive Care Med       Date:  2014-11-01       Impact factor: 17.440

9.  Ebola virus disease in mice with transplanted human hematopoietic stem cells.

Authors:  Anja Lüdtke; Lisa Oestereich; Paula Ruibal; Stephanie Wurr; Elisa Pallasch; Sabrina Bockholt; Wing Hang Ip; Toni Rieger; Sergio Gómez-Medina; Carol Stocking; Estefanía Rodríguez; Stephan Günther; César Muñoz-Fontela
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

10.  Ebolavirus classification based on natural vectors.

Authors:  Hui Zheng; Changchuan Yin; Tung Hoang; Rong Lucy He; Jie Yang; Stephen S-T Yau
Journal:  DNA Cell Biol       Date:  2015-03-24       Impact factor: 3.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.